Immatics: PRAME Is Becoming More Than A Single-Asset Story
Immatics is evolving into a PRAME-focused oncology platform with three monetization paths, not just a single-asset cell therapy play. IMTX's lead asset, anzu-cel, is in Phase 3 for advanced melanoma, but broader value lies in its layered PRAME franchise and pipeline expansion. IMTX maintains a strong cash runway into 2028, enabling critical clinical milestones without distressed financing or near-term capital risk.
Immatics (IMTX) Reports Q1 Loss, Lags Revenue Estimates
Immatics (IMTX) came out with a quarterly loss of $0.5 per share versus the Zacks Consensus Estimate of a loss of $0.42. This compares to a loss of $0.35 per share a year ago.
All You Need to Know About Immatics (IMTX) Rating Upgrade to Buy
Immatics (IMTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Immatics: PRAME Leader's Transition To Commercial Reality
Immatics executes a three-wave strategy, progressing from melanoma treatment to broader solid tumors and scalable bispecific TCR therapeutics. IMTX's $505.8M cash position funds operations through 2027, covering BLA submission and anticipated commercial launch, reducing near-term financing risk. Anzu-cel's Phase 3 SUPRAME trial and IMA203CD8's promising ovarian cancer data support a robust, expanding clinical pipeline with significant addressable markets.
Immatics (IMTX) Reports Q3 Loss, Misses Revenue Estimates
Immatics (IMTX) came out with a quarterly loss of $0.49 per share versus the Zacks Consensus Estimate of a loss of $0.5. This compares to a loss of $0.12 per share a year ago.
Immatics: Multiple Clinical Catalysts In Q4'25 And 2026
IMTX is advancing Anzu-cel, a T-cell receptor therapy for melanoma with potential for significant annual revenue. Anzu-cel offers advantages over IOVA's Amtagvi, including less invasive cell collection, faster turnaround, and no need for high-dose IL-2. Phase 1b data show a 56% objective response rate and 91% disease control rate in melanoma patients treated with IMTX's therapy.
Immatics (IMTX) Reports Q2 Loss, Misses Revenue Estimates
Immatics (IMTX) came out with a quarterly loss of $0.66 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to a loss of $0.18 per share a year ago.
Does Immatics (IMTX) Have the Potential to Rally 174.54% as Wall Street Analysts Expect?
The mean of analysts' price targets for Immatics (IMTX) points to a 174.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Immatics N.V.: Trading Below Cash, But Not Without Reason
Immatics' lead asset, IMA203, shows promising early data with a 57% ORR in heavily pretreated patients, but toxicity concerns remain. Financially, IMTX has a $540mn market cap and $628mn cash, but negative enterprise value due to early-stage data and long catalyst desert. Phase 3 trial for IMA203 will produce interim data in early 2026, with no clear topline data timeline, creating uncertainty.
Immatics (IMTX) Upgraded to Buy: What Does It Mean for the Stock?
Immatics (IMTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
What Makes Immatics (IMTX) a New Buy Stock
Immatics (IMTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Immatics (IMTX) Reports Q3 Loss, Tops Revenue Estimates
Immatics (IMTX) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.35 per share a year ago.
